Asset Details
Do you wish to reserve the book?
Tolerance of Plasmodium falciparum mefloquine-resistant clinical isolates to mefloquine-piperaquine with implications for triple artemisinin-based combination therapies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tolerance of Plasmodium falciparum mefloquine-resistant clinical isolates to mefloquine-piperaquine with implications for triple artemisinin-based combination therapies
Do you wish to request the book?
Tolerance of Plasmodium falciparum mefloquine-resistant clinical isolates to mefloquine-piperaquine with implications for triple artemisinin-based combination therapies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tolerance of Plasmodium falciparum mefloquine-resistant clinical isolates to mefloquine-piperaquine with implications for triple artemisinin-based combination therapies
2025
Overview
Triple artemisinin-based combination therapies (TACTs) have been proposed to delay the emergence of multidrug-resistant
Plasmodium falciparum
by combining two partner drugs with an artemisinin derivative. Among these, mefloquine–piperaquine (MQ–PPQ) is a leading candidate, based on the assumption that simultaneous resistance to both partner drugs would be difficult to develop. Here, we assess the efficacy and resistance potential of MQ–PPQ using Cambodian clinical isolates with distinct resistance profiles. We find that MQ resistance confers significant cross-tolerance to the MQ–PPQ combination, whereas PPQ-resistant and -sensitive strains remain susceptible. Under repeated MQ–PPQ pressure for four months, parasites rapidly acquire MQ–PPQ tolerance, driven by
pfmdr1
amplification. Mechanistic investigations reveal that MQ inhibits PPQ accumulation in a dose-dependent manner, providing a functional explanation for the compromised efficacy of the combination. These findings demonstrate that MQ resistance alone can undermine MQ–PPQ TACT efficacy, calling into question the strategic rationale of this combination and underscoring the need for alternative regimens with a lower risk of resistance selection.
Triple artemisinin-based combination therapies, including mefloquine–piperaquine (MQ–PPQ), may delay emergence of multidrug-resistant strains. Here the authors show that resistance to mefloquine alone reduces the efficacy of the MQ-PPQ combination therapy, and that the interaction between the two drugs further inhibits piperaquine’s activity.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 45/22
/ 45/23
/ Antimalarials - pharmacology
/ Antimalarials - therapeutic use
/ Artemisinins - therapeutic use
/ Cambodia
/ Drugs
/ Humanities and Social Sciences
/ Humans
/ Malaria
/ Malaria, Falciparum - drug therapy
/ Malaria, Falciparum - parasitology
/ Mefloquine - therapeutic use
/ Multidrug Resistance-Associated Proteins - genetics
/ Multidrug Resistance-Associated Proteins - metabolism
/ Plasmodium falciparum - drug effects
/ Plasmodium falciparum - genetics
/ Plasmodium falciparum - isolation & purification
/ Quinolines - therapeutic use
/ Science
